Study shows tofacitinib medication can fix porousness absconds in the digestive tract Kumar Jeetendra | October 6, 2020 A team of researchers led by biomedical scientist Declan F. McCole in the University of California, Riverside, has found that the medication tofacitinib, also called Xeljanz and approved by the FDA to treat rheumatoid arthritis and ulcerative colitis, can fix permeability defects in the intestine. Study results appear in the Journal of Crohn’s and Colitis. …
Seeing how the malaria can withstand fever’s warmth Kumar Jeetendra | October 6, 2020 Even when a man suffering from malaria is burning up with fever and too ill to operate, the little blood-eating parasites lurking inside them continue to flourish, relentlessly growing and multiplying as they gobble up the host’s red blood cells. The single-celled Plasmodium parasites that cause 200 million cases of malaria annually can withstand feverish …
Covid immunization: Bharat Biotech to utilize ViroVax’s adjuvant for Covaxin Kumar Jeetendra | October 5, 2020 Trials, will use adjuvant Alhydroxiquim-II to boost immune response and longer lasting immunity. The technology has been used under this licensing arrangement with US-based ViroVax. Adjuvant is used to boost the vaccine efficacy. Covaxin is an inactivated vaccine derived from a strain of SARS-CoV-2 virus, isolated in the National Institute of Virology (NIV), Pune under …
Parkinson’s disease is a free danger factor for biting the dust from COVID-19, study recommends Kumar Jeetendra | October 3, 2020 A fresh study of about 80,000 patients shows that people with Parkinson’s disease (PD) have a 30% greater risk of dying from COVID-19 than individuals without the neurodegenerative condition. The new analysis conducted by researchers at University of Iowa Health Care based on patient information in the TriNetX COVID-19 research network suggests that Parkinson’s disease …
Coronavirus immunization turn out expected in under 3 months in UK: The Times Kumar Jeetendra | October 3, 2020 A mass roll-out of a COVID-19 vaccine in Britain could be completed in as little as three months, the Times reported, citing government scientists. Scientists working on the Oxford vaccine hope regulators approve it before the beginning of 2021, the paper said. A complete COVID-19 immunization programme, which would exclude children, could be faster than …
Role of Aerogen Nebulization in High Flow Oxygen Therapy Kumar Jeetendra | October 2, 2020 High flow oxygen therapy is a form of respiratory support used in the hospital where oxygen, often in conjunction with compressed air and humidification, is delivered to a patient at rates of flow higher than that delivered traditionally in oxygen therapy. High flow oxygen therapy is intended to Eliminate most of the anatomic dead space …
AstraZeneca resumes COVID-19 immunization preliminary in Japan, US still stopped Kumar Jeetendra | October 2, 2020 AstraZeneca Plc said on Friday clinical trials of its experimental COVID-19 vaccine declared in Japan, while adding that it was in talks with regulators on data necessary to restart studies in the United States, where they remain halted. Several global trials of the vaccine, AZD1222, were put on hold last month after an unexplained illness …
Russia to start Phase III preliminaries of second COVID-19 antibody in November-December: Report Kumar Jeetendra | October 2, 2020 Russia begins Phase III trials of a second possible vaccine against COVID-19, developed by Siberia’s Vector Institute, in November-December, the TASS news agency cited Russian consumer security watchdog Rospotrebnadzor as saying on October 2. Early-stage clinical trials for the vaccine have been completed on Wednesday.
Researchers distinguish interesting examples in COVID-19 transmission in India Kumar Jeetendra | October 1, 2020 Researchers, including those from the Government of Tamil Nadu, and Andhra Pradesh, have conducted one of the largest analysis of COVID-19 epidemiology to date, and have discovered that both cases and deaths due to the disease are more heavily concentrated in the 40-69 year age group in India than is seen in high-income nations, among …
Moderna COVID-19 antibody seems safe, gives indications of working in more seasoned grown-ups: Study Kumar Jeetendra | September 30, 2020 Results from an early safety study of Moderna Inc’s coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those found in younger adults, with side effects about on par with high-dose flu shots, researchers said on Tuesday. The study, published in the New England Journal of Medicine, offers …
Russia finishes clinical preliminaries of second potential COVID-19 immunization Kumar Jeetendra | September 30, 2020 Russia has completed clinical trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute, the RIA news agency mentioned Russian customer safety watchdog Rospotrebnadzor as saying on Wednesday The institute completed early-stage human trials, known as Phase II, earlier this month.
Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay Kumar Jeetendra | September 30, 2020 Mechelen, Belgium, 30 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has received a EUR 1.2 million grant from VLAIO, the Flanders organization for Innovation & Entrepreneurship, for the development of the highly innovative GeneFusion Assay on its easy, rapid molecular …
